Since its inception in February 2015, Janssen R&D LLC's Disease Interception Accelerator (DIA) – a research initiative focused on prediction and preemption of disease – has signed 24 agreements. The firm highlighted the anniversary March 22 with the unveiling of two new ones to identify disease pathways associated with chronic obstructive pulmonary disease and to identify biomarkers in gestational diabetes mellitus.
Janssen Expanding Its Disease Interception Efforts
Through a series of research agreements, J&J arm is seeking to create new business models teaming a single internal expert with a host of external researchers in six priority therapeutic areas.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
• By
The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.